US equities
|
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Harmony Biosciences Holdings, Inc. - Common Stock
(NQ:
HRMY
)
39.64
+0.07 (+0.18%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Harmony Biosciences Holdings, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
Harmony Biosciences Holdings (NASDAQ:HRMY) Reports Q4 2025 Revenue In Line, Earnings Miss Amid Pipeline Investment
↗
February 24, 2026
Via
Chartmill
Topics
Earnings
Harmony Biosciences Reports Strong 2025 Financial Results and Reiterates 2026 Net Revenue Guidance of Over $1 Billion
February 24, 2026
From
Harmony Biosciences Holdings, Inc.
Via
Business Wire
Harmony Biosciences Holdings (NASDAQ:HRMY) Emerges as a Compelling Value and Growth Pick
↗
February 20, 2026
Via
Chartmill
HRMY Stock Rises On Fresh FDA Approval For Wakix Tablets In Children But Wall Street Eyes Further Rally
↗
February 17, 2026
The FDA has approved Harmony’s Wakix tablets for the treatment of cataplexy in pediatric patients aged 6 years and older with narcolepsy.
Via
Stocktwits
Harmony Biosciences Receives U.S. Food and Drug Administration Approval for WAKIX® (pitolisant) for the Treatment of Cataplexy in Pediatric Narcolepsy
February 17, 2026
From
Harmony Biosciences Holdings, Inc.
Via
Business Wire
Harmony Biosciences Holdings (NASDAQ:HRMY) Presents a Compelling Mix of Strong Fundamentals and Bullish Technical Setup
↗
February 17, 2026
Via
Chartmill
Harmony Biosciences Holdings (NASDAQ:HRMY) Emerges as a Prime GARP Investment
↗
February 13, 2026
Via
Chartmill
Harmony Biosciences Holdings (NASDAQ:HRMY) Combines Strong Fundamentals with Bullish Technical Setup
↗
January 26, 2026
Via
Chartmill
Harmony Biosciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
February 10, 2026
From
Harmony Biosciences Holdings, Inc.
Via
Business Wire
Harmony Biosciences Chief Financial Officer Sells Shares Again After Previous Exit From Company Equity
↗
February 01, 2026
This top executive at Harmony Biosciences previous sold all of his direct shares in the company in early January 2026. But towards the end of the month, some options and restricted stock units vested,...
Via
The Motley Fool
Topics
Regulatory Compliance
Harmony Biosciences' CFO Sells All of His Insider Shares, Worth $752,800
↗
January 31, 2026
This bioscience company has had promising financials, yet one of its top executives exited his entire direct equity ownership in mid-January 2026.
Via
The Motley Fool
Topics
Regulatory Compliance
Harmony Biosciences Holdings (NASDAQ:HRMY) Embodies the Affordable Growth Strategy
↗
January 09, 2026
Via
Chartmill
Harmony Biosciences Holdings (NASDAQ:HRMY) Presents a Compelling Value and Quality Investment Case
↗
January 06, 2026
Via
Chartmill
Harmony Biosciences' CFO Sells All of Her Insider Shares, Worth $752,800
↗
January 31, 2026
This bioscience company has had promising financials, yet one of its top executives exited her entire direct equity ownership in mid-January 2026.
Via
The Motley Fool
Topics
Regulatory Compliance
How Harmony Biosciences Can Prove Its Skeptics Wrong
↗
January 28, 2026
The biotech company is looking for multiple successes in the coming years.
Via
The Motley Fool
Topics
Intellectual Property
Harmony Biosciences' Sales and Profits Have Soared. Why Hasn't Its Stock Followed?
↗
January 27, 2026
Some investors haven't gotten answers to their questions about the biotech stock's past and future.
Via
The Motley Fool
Topics
Initial Public Offering
Intellectual Property
I Was Shocked to Find This Value-Priced Biotech Growth Stock
↗
January 26, 2026
But deciding if it's a good buy takes a little more looking.
Via
The Motley Fool
Harmony Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 07, 2026
From
Harmony Biosciences Holdings, Inc.
Via
Business Wire
Rhythm Pharmaceuticals Faces Gravity: FDA Delays and Valuation Pressures Cool 2025’s Biotech Darling
December 30, 2025
As the final trading days of 2025 wind down, Rhythm Pharmaceuticals (Nasdaq: RYTM) finds itself at a critical crossroads. After a meteoric rise that saw the stock gain over 100% through the first three...
Via
MarketMinute
Topics
ETFs
Economy
World Trade
Harmony Biosciences Holdings (NASDAQ:HRMY) Emerges as a Prime Growth at a Reasonable Price (GARP) Candidate
↗
December 18, 2025
Harmony Biosciences (HRMY) exemplifies Growth at a Reasonable Price (GARP) with strong sales growth, robust profitability, and a solid financial base, all at a compelling valuation.
Via
Chartmill
Beacon Biosignals Announces Partnership with Harmony Biosciences to Advance Objective Clinical Endpoints in Hypersomnia Conditions Through Quantitative EEG
December 16, 2025
From
Beacon Biosignals
Via
GlobeNewswire
Harmony Biosciences Holdings (NASDAQ:HRMY) Presents a Compelling Value Investment Case
↗
December 12, 2025
Harmony Biosciences (HRMY) presents a classic value investing case with strong profitability, a healthy balance sheet, and solid growth—all at a compellingly low valuation.
Via
Chartmill
Harmony Biosciences Presents Clinically Meaningful Open-Label Extension Study Effectiveness Data for EPX-100 in Dravet Syndrome
December 08, 2025
From
Harmony Biosciences Holdings, Inc.
Via
Business Wire
Harmony Biosciences to Present New Open-Label Extension Data from Phase 3 ARGUS Trial at the 2025 American Epilepsy Society Annual Meeting
December 02, 2025
From
Harmony Biosciences Holdings, Inc.
Via
Business Wire
Harmony Biosciences Holdings (NASDAQ:HRMY) Presents a Compelling Case for Growth at a Reasonable Price
↗
November 26, 2025
Harmony Biosciences (HRMY) is a top GARP stock with strong growth, stellar profitability, and a surprisingly cheap valuation. A compelling growth at a reasonable price pick.
Via
Chartmill
Harmony Biosciences Announces Positive Results From the Pivotal Bioequivalence Study for Pitolisant Gastro-Resistant Formulation
November 24, 2025
From
Harmony Biosciences Holdings, Inc.
Via
Business Wire
Harmony Biosciences Announces Initiation of First-In-Human Study With Potential Best-In-Class Orexin 2 Receptor Agonist (BP1.15205) for Central Disorders of Hypersomnolence
November 19, 2025
From
Harmony Biosciences Holdings, Inc.
Via
Business Wire
Harmony Biosciences to Participate in Upcoming Investor Conferences
November 18, 2025
From
Harmony Biosciences
Via
Business Wire
Harmony Biosciences Holdings (NASDAQ:HRMY) Appears Undervalued with Strong Fundamentals
↗
November 15, 2025
Harmony Biosciences (HRMY) appears undervalued with a low P/E ratio, strong profitability, and impressive growth, suggesting a potential market opportunity.
Via
Chartmill
Harmony Biosciences Holdings (NASDAQ:HRMY) Beats Q3 2025 Estimates Despite Muted Market Reaction
↗
November 04, 2025
Harmony Biosciences Q3 2025 earnings beat estimates with strong WAKIX growth. Despite the beat, stock dipped slightly in pre-market trading.
Via
Chartmill
Topics
Earnings
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
